Physician profile
Robert G Mignone
NPI 1518224153
$90,622.91
in general payments reported to CMS, 2019-2025
18 companies · $24K in 2025
The $24K reported for 2025 was more than what 99% of Otolaryngology/Facial Plastic Surgery providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $324 · 2021: $1,986 · 2022: $3,875 · 2023: $18K · 2024: $43K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $58K · Honoraria: $13K · Food and Beverage: $7,991 · Travel and Lodging: $5,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $57,940.00 |
| Honoraria | $13,200.00 |
| Food and Beverage | $7,991.21 |
| Travel and Lodging | $5,005.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $59,413.39 | 2022-2025 | |
| Davol INC. | $26,491.39 | 2020-2025 | Arista Ah Flexitip |
| Inspire Medical Systems, INC. | $2,805.06 | 2022-2025 | Inspire |
| Intersect Ent, INC. | $595.60 | 2019-2021 | |
| Optinose US, INC. | $488.60 | 2023-2025 | |
| Medtronic, INC. | $263.02 | 2025 | Propel |
| Stryker Corporation | $192.67 | 2019-2025 | Xpress Loprofile |
| Glaxosmithkline, LLC. | $138.31 | 2023-2025 | Nucala |
| Neurent Medical Limited | $56.64 | 2025 | Neuromark System, Neuromark Radiofrequency Console |
| Csl Behring | $40.34 | 2025 | Andembry |
| Smith+Nephew, INC. | $31.88 | 2020 | |
| Hikma Pharmaceuticals USA | $16.34 | 2023 | Ryaltris |
| Genzyme Corporation | $16.26 | 2024 | |
| Phathom Pharmaceuticals, INC. | $15.46 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $15.27 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $14.78 | 2025 | Tezspire |
| Blueprint Medicines Corporation | $14.70 | 2023 | Ayvakit |
| Aimmune Therapeutics, INC. | $13.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mignone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.